Organon Opens Experience Center in the Netherlands on International Women’s Day
The global pharmaceutical company celebrates 100th year of contributing to women’s health
The global healthcare company Organon has opened its new Experience Center in the Netherlands to coincide with International Women’s Day and the company’s 100th anniversary. The Experience Center in the city of Oss offers a unique insight into the pharmaceutical company which is known for the contraceptive pill and its contribution to women’s health around the world.
As part of the opening celebration, Organon hosted a symposium with experts in the field of women’s health and policy and leaders from politics, government and business. Speakers included the Deputy Ambassador of the United States, Aleisha Woodward, the Mayor of Oss, Wobine Buijs, Organon Oss Site Director, Wenny Raaijmakers, and Managing Director of Organon Benelux, Petra Willems. Representing the Netherlands Foreign Investment Agency and the Invest in Holland network was Sandra de Wild-Chardonnens, Sector Specialist Life Sciences & Health.
Healthcare solutions that benefit society
Willems said: ‘Anyone who looks at the Organon of today sees a life science hub that is working on pharmaceutical innovation. With one clear objective: to honor the commitment to improve women’s health. If women are less hampered by symptoms and/or conditions that can be prevented or treated in a better way, then so much more female potential is released. And that benefits society.’
In addition, there is significant investment in Oss, where Organon’s largest production site in the world is located. On this site, new robot production lines, (extrusion) machines and multiple new packaging lines will be installed. All told, Organon is currently investing around 40 million euros in the expansion of the advanced manufacturing facilities in Oss.
Innovating in the Netherlands life sciences & health ecosystem
Organon started as an independent company in Oss in 1923 and became a spin-off of the American company Merck & Co (MSD) in 2021. In the past two years, the company has further expanded its healthcare solutions as part of the Dutch life sciences & health ecosystem.
For example, with the acquisition of Alydia Health (for a solution in the field of severe bleeding after childbirth), a collaboration with Obseva (for research into the treatment of premature childbirth) and the acquisition of Forendo Pharma (which is conducting research into endometriosis, among other things). Organon has recently started a collaboration with Cirqle that is conducting research into non-hormonal contraception. In April 2022, Organon announced that it would significantly expand production in the Netherlands.
As an independent healthcare company, Organon is committed to improving the health of women worldwide and to increasing gender and gender-specific healthcare. It manufactures more than 60 medicines and other products across a range of areas including reproductive health, heart disease, dermatology, allergies and asthma. With approximately 1,200 employees in Oss and Amsterdam (Benelux office); the company employs more than 9,000 people worldwide.
Source: Organon news release8 March 2023